Todd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 4,174 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.76, for a total transaction of $15,694.24. Following the sale, the insider directly owned 145,718 shares of the company’s stock, valued at approximately $547,899.68. This represents a 2.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Todd Alfred Carter also recently made the following trade(s):

• On Tuesday, February 10th, Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.85, for a total value of $13,571.25.

Voyager Therapeutics Price Performance

Shares of VYGR traded up $0.04 during mid-day trading on Thursday, reaching $4.13. The stock had a trading volume of 151,278 shares, compared to its average volume of 584,842. The firm has a market cap of $229.63 million, a price-to-earnings ratio of -1.91 and a beta of 1.30. The business’s fifty day moving average is $3.86 and its 200 day moving average is $4.11. Voyager Therapeutics, Inc. has a 52-week low of $2.64 and a 52-week high of $5.55.

Wall Street Analyst Weigh In

VYGR has been the subject of several research analyst reports. HC Wainwright lowered their target price on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Finally, Wall Street Zen lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently bought and sold shares of the stock. Bank of Montreal Can purchased a new position in shares of Voyager Therapeutics during the second quarter worth approximately $36,000. Wexford Capital LP purchased a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $42,000. ProShare Advisors LLC acquired a new stake in shares of Voyager Therapeutics in the 4th quarter valued at approximately $44,000. CIBC Asset Management Inc purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $45,000. Finally, Los Angeles Capital Management LLC acquired a new position in Voyager Therapeutics during the second quarter worth $50,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.